A B S T R A C T In 35 patients maintained solely on liquid formula diets, chromic oxide has been evaluated as an internal standard for balance studies that require stool collections. In 28 patients the excretion of chromic oxide was ideal: steady states were attained in which mean daily output was 90% (or more) of mean daily intake. In these patients corrections for fecal flow could validly be applied.
A B S T R A C T In 35 patients maintained solely on liquid formula diets, chromic oxide has been evaluated as an internal standard for balance studies that require stool collections. In 28 patients the excretion of chromic oxide was ideal: steady states were attained in which mean daily output was 90% (or more) of mean daily intake. In these patients corrections for fecal flow could validly be applied.
In patients who excreted the marker ideally, the availability of chromic oxide balance data made possible the calculation of pool sizes and turnover rates of unexcreted intestinal content. These indexes bore little relationship to the usual clinical descriptions of bowel habits. In some patient who had daily bowel movements, pool sizes were very large and daily turnover was small, i.e., a large proportion of the colonic contents was not excreted for surprisingly long periods. It is critically important for investigators to recognize this possibility when carrying out balance studies for fecal constituents that may be altered by bacterial action within the gut lumen: for instance, in 6 patients a significant inverse correlation was found between daily fecal turnover and degradative losses of large amounts of dietary /8-sitosterol.
INTRODUCTION
In metabolic balance studies stools collected during a given period of time (lo not necessarily reflect the biological events that take place in the intestine during the collection periodl; even 4-day collections rarely represent exactly 96 hr in the transit of any particular portion of the intestinal contents. Hence, there is a need for an inert marker which can be incorporated into the food intake, the excretion of which can indicate the completeness of stool collections and permit corrections for variations in fecal flow. Chromic oxide (CrO:,) has been wi(lely used in man since 1947 (1) for these purposes, since it is nontoxic, readily measurable in the feces, and appears to be completely unabsorbable.
In view of the widening use of formula feeding in metabolic balance stu(lies, we have evaluated Cr20. as a marker in patients fed a residue-free diet. In the course of that exploration, we noted that the pool size of unexcreted colonic contents, as well as the daily percentage turnover of that pool, could be estimated from Cr.,O excretion data. It then became clear that these estimates bore little relationship to such common clinical indexes as the size and frequency of bowel movements
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which seem, therefore, to give a poor indication of the residence time of intestinal contents within the colon. Nevertheless, this residence time determines to some extent the degree of bacterial growth in the colon; this, in turn, could affect the degree of degradation of various metabolites by bacteria before evacuation.
This paper reports the usefulness of Cr2O8 as a marker in formula-fed patients, and describes certain anomalies in the physiology of colonic function which can cause errors in balance experiments but which can be recognized if an internal standard is being used.
METHODS

Clinical aspects
The study was carried out on 35 patients (Table I) , 15 males and 20 males, 11-70 yr of age, admitted to the metabolic ward of The Rockefeller University Hospital for long-term investigation of cholesterol metabolism. 4 patients were normocholesterolemic; all others were affected with some form of hypercholesterolemia and (or) hyperglyceridemia, and 19 had ischemic heart disease. In none was there clinical evidence of gastrointestinal disease. All were ambulatory and were urged to exercise within the limitations set by the severity of their coronary artery disease.
Patients were maintained solely on orally administered liquid formula feedings, supplemented with vitamins and minerals as previously described (3), throughout their hospital stay. 26 different dietary regimens were imposed; in all but 3 regimens the protein intake was 15% of total calories, and in these 3, fed to children, protein intake was increased to 20%. 16 formulas supplied 40% of calories as fat, and in the others the fat content varied from 0 to 34% ; 8 different dietary fats were used. These variations had no effect on the aims or results obtained in the present study. In all cases, caloric intakes were adjusted in order to maintain the patient's body weight constant.
Five feedings were given at 3-hr intervals each day, and with each feeding one or two tablets (see below) each containing 60 mg of Cr203 were dispensed: a 300 mg per day dosage was chosen in most cases because it permitted an accurate estimation of the chromium content in a 0.5-1.5 g aliquot of fecal homogenate. Complete fecal collections were made, and in most cases were pooled in 4-day collections throughout the study period, except for the 1st and last 8 days, when 24-hr collections were made. Stools were homogenized as previously described (4) ; 6-oz aliquots were immediately transferred to screw-cap bottles for storage at 4VC. The duration of study varied from 33 to 302 days.
6 patients received approximately 10 ,uc of "Cr,0,, either as a single tablet or in divided doses (2-5 tablets).
In 5 of the 6 patients the radioactive tablets were substituted for nonlabeled tablets during chronic administration of the marker; the 6th patient received radioactive Cr20, without prior exposure to the marker.
Preparation of chromic oxide for tableting
Tablets of reagent grade Cr203 (chromium sesquioxide, Fisher Scientific Company, Pittsburgh, Pa.) were prepared in large batches according to standard pharmaceutical techniques by Lederle Laboratories Div. (American Cyanamid Co., Pearl River, N. Y.; Mr. Adolph E. Tiesler). Each tablet contained 60 mg of Cr,0,, 120 mg of microcrystalline cellulose, and 5 mg of talc. The coefficient of variation for a total tablet weight of 185 mg was less than 2% (number of tablets = 50), and random sampling throughout the study confirmed the manufacturer's estimate of Cr2O3 content, within the error of our analytical method. If held in the mouth, the tablet would rapidly disintegrate into powder.
Analyses were made for trace metals by flame emission spectroscopy through the generous cooperation of Dr. Bert L. Vallee, Harvard Medical School. Elements other than chromium were not found in the milled or unmilled powder, or in acid washings, in concentrations that could cause concern from a toxicological viewpoint. taken at the surface and at the bottom of the storage jar showed no significant differences in chromium content. Storage at 4VC for long periods did not influence Cr2O8 measurements in fecal samples: replicate determinations over several months showed a coefficient of variation of less than 5%. 10 replicate determinations over a 7 month period in feces diluted 1: 2 showed a coefficient of variation of 2.8% with a mean difference between duplicates of 2.2% (± 1.5%)o.
Preparation of radioactive Cr203 tablets
Measurement of *y-emission in feces containing 51Cr2O3
was carried out in a well-type scintillation counter at a constant volume of 3.5 ml. Fecal homogenates were counted directly, since Roche, Perez-Gimenez, Layrisse, and Di Prisco (6) had shown that in fecal homogenates diluted 1:1 there was no self-absorption of radioactivity.
Counting efficiency was 3.1%; samples and background were counted for sufficiently long times that the error of counting was lower than 5%o. Counts in fecal homogenates of 3.5 ml volume were always related, for decay correction, to counts obtained with a 51Cr20: tablet set aside as a standard. It was necessary to increase the count in feces by 12.5% because of the difference in geometry between a tablet and 3.5 ml of suspension. This correction factor was obtained by counting soluble Na radiochromate in a volume equal to that of a tablet, then adding water to bring the volume to 3.5 ml and recounting.
Gamma-ray counting of urine was carried out on the residue obtained by lyophilization; blood samples were hemolyzed with small amounts of sodium dodecyl sulfate, then counted as described above for feces.
Terms and calculations
Steady state of Cr203 excretion refers only to the part of the study period when the mean daily excretion equals the daily intake.
Ideality of Cr203 excretiom is, by definition, achieved only if the steady state is attained. Any patient not achieving the steady state is considered nonideal with regard to excretion of Cr203; this finding should serve to warn the investigator that the excretion of other fecal constituents may also be nonideal.
Cr2:0, pool sire refers to the amount of marker present in the intestinal tract at any given time after the steady state is attained. It is measured directly as the amount collected in the feces after the intake has been discontinued. Also, it can be calculated at any time during the study as the difference between the total administered and total recovered; however, this estimate is subject to greater inaccuracy than the former direct measurement because of the accumulation of errors made in analyses of many stool collections.
Fecal pool size represents the weight (g) of unexcreted intestinal contents (presumably that mainly in the colon).
During the steady state it is equal to the Cr2Os pool size (mg) divided by the mean daily concentration of Cr20s (mg/g of feces). Clearly, the fecal pool calculation is an oversimplification: since there must be a gradient of Cr203 concentration from the cecal to the sigmoid end of the large bowel, because of water absorption during colonic transit, pool sizes calculated in this manner are minimum estimates.
Daily Cr203 turnover (%) represents an average figure for the percentage of the Cr203 pool which is excreted daily. In the steady state it is the ratio of the mean daily Cr203 output to the Cr203 pool size, multiplied by 100.
Daily fecal turnover represents the percentage of the fecal pool that is excreted daily, on the average. In the steady state it is the ratio of the average daily fecal weight (g) to the fecal pool size, multiplied by 100.
Fractional turnover rate of '1Cr20s was calculated on the assumption that the elimination of 51Cr203 follows first-order kinetics: 
Measurements of fecal steroids
Fecal neutral and acidic steroids were measured by techniques developed in this laboratory and published in detail elsewhere (4, 8) . The raw data were corrected for degradation of the sterol ring structure as previously described (9) (10) (11) .
RESULTS
Cr2O3 balance data in 28 patients with ideal excretion of the marker transit time In 9 patients who had daily bowel movements and who later were shown to excrete Cr2O8 ideally, the transit time of the marker (measured chemically) was 2 days. However, there was no relationship between appearance time, average daily fecal weight, and percentage of daily dose excreted when the marker was first detected. When 51Cr2O3 was given later to 4 of these patients, radioactivity was first detectable in the stools on the 2nd day in each case.
Attainment of steady state. Under ideal balance conditions with daily administration of the marker, the concentration of Cr2,O in the feces should increase rapidly to reach a plateau. Similarly, daily output of Cr2O3 should rise until it first exceeds daily intake and then fluctuates around 100%o of intake, at which time a steady state of balance is attained and the amount of Cr2O3 retained in the intestinal tract (the pool size) has become constant.
Although attainment of the steady state is reflected by a tendency for a cumulative recovery curve to be hyperbolic and to approach the 100%o limit with time, that limit is necessarily reached at a later time. By contrast, if there is a continual retention of marker, the concentration of Cr2O3 in feces may still reach a plateau and so may a cumulative recovery curve. However, the plateau for cumulative recovery will be less than 100%o (for example, 66%o if % of the intake is retained each day); even when the daily retention of marker is a constant fraction of the daily intake, the balance is nonideal and a true steady state is not reached. Fig. 1 illustrates these points with data obtained in patient 2, in whom the Cr2O3 balance data met the criteria of ideality. The concentration of marker in the feces reached a maximum in 4 days, and remained relatively constant thereafter until the end of this 172 day study. Balance data exceeded Cr203 concentration (mg/g feces) FIGURE 1 Excretion pattern of Cr2O, administered daily in an "ideal" patient. Patient 2, given 300 mg of Cr2O: per day, had a transit time of 2 days and rapidly attained a plateau of fecal concentration of Cr203 (4 days Table II describes studies of 65-180 days' duration in 6 patients in whom the steady state was examined in detail. This analysis required total stool collections during the entire period of Cr2O3 administration as well as for several days thereafter, in order to determine the total amount of marker retained in the intestine after oral intake ceased. In these 6 patients at least 93% of the daily intake of Cr2O3 was recovered in the feces during the steady state, and in the 4 who were given 51Cr2O3 the recovery was 94%o or more.
While the mean daily fecal concentration varied considerably from patient to patient, in each the variability from one collection period to another was relatively small, i.e., the coefficient of variation was less than 25 % in all cases. A plateau of fecal Cr203 concentration was reached in 4-12 days, and the steady state after 6-18 days. Slowness in reach- ing the steady state was perhaps due to the fact that residue-free formula feeding was employed in this study (although we have not tested the effect of added residue). Nevertheless, it must be stressed that the regimen per se did not preclude attainment of the steady state. In 22 other patients, mean daily Cr2O3 excretion closely approximated mean daily intake (+ 10%o) over the many days (24-220) in which 4-day stool collections were continuously made. Although all the information recorded in Table II was not sought in those 22 patients, the demonstration of equal intake and output indicated that the excretion of Cr2O.z was ideal and that the steady state had been attained in these formula-fed patients.
Pool sizes and turnover rates (Table II) . Table  II shows that pool sizes varied over a 5-fold range in these 6 patients, and daily turnover varied from 20 to 100%o. In other terms, the amount of unexcreted intestinal contents varied from 90 to 450 g, and the amount of unexcreted Cr2O3 varied from 1 to 5 daily doses of the internal standard. Despite large variations in colonic emptying, the excretion of Cr2O3 was ideal in all these patients; this indicated that balance data for products excreted in the feces could be corrected meaningfully for variations in fecal flow.
This (None of them showed evidences of intestinal disease or greater variations in the usual indexes of bowel function than the much larger group in whom the excretion of marker was ideal.) First, in the 4 patients in whom the transit time of Cr2O3 was measured, it varied from 3 to 5 days, in contrast to 2 days in 9 ideal patients. In the second place, the 7 patients excreted the marker so slowly, and consistently retained so much of the daily intake, that the steady state was never reached; indeed, during the 43-302 days of study these patients excreted only 61-80o of the cumulative intake. Third, while the concentration of CrO3 per gram of feces was approximately the same as in the ideal group described in Table II , the variation in concentration of marker from one period to the next varied much more widely: in 3 patients the coefficient of variatoin was 38-41 o, whereas in only 1 of 6 ideal patients (Table II) was the coefficient of variation greater than 20%7o.
Accumulation and sequestration. Fig. 2 plausible; a more likely explanation for the discrepancy is that the sequestered Cr20, was more highly concentrated than that excreted in feces. F 4 1 Not only was the internal standard sequestered in this patient; in period III (Fig. 3) feces highly dose) concentrated in CrO3 and in /-sitosterol were excreted as the Cr2O3 balance became temporarily positive for the only two stool collection periods in this long study. This finding has led us to the conclusion that, in patients who fail to reach a steady state for excretion of Cr2O3, balance data for other fecal constituents must be considered to be unreliable. This sequestration of marker plus /3-sitosterol was demonstrated about a year later in patient 11, and also in a second patient (patient 17) in whom the excretion of CrO3 was nonideal.
Use of Cr2O, to correct fecal flow The plots of 51Cr elimination in the two patients i the parent with the largest and smallest fecal pool sizes of the acterial con-group so tested (patients 2 and 5) are presented ine, increas-in Fig. 4 . There was good agreement between the aTG, sodium fecal CrO3 turnover rate calculated from the Cr.03 ,balance data and that derived from the value ined 19.4 g, of k in the 51CrO3 experiments. For patient 5 )3 pool size, these values were 56 and 54%o, and for patient 2 )ncentration they were 20 and 22%, respectively. Regrettably. these kinetic data agreed well with those calculated from Cr2O: balance data (see Table II ).
2lCr, 3 studies were not carried out in any of the nonideal patients. Nonabsorbability. Table II shows that in 6 patients the recovery of CrO3 administered daily for 65-180 days was 90% or greater. Indeed, in patients 1-4 the recovery was essentially complete.
As a further test of the nonabsorption of Cr203, five experiments with 51Cr203 were undertaken.
The labeled compound (10 /tc) was given in a single day to patients who were already receiving 300 mg of unlabeled Cr203 per day; measurements were made of radioactivity in feces until no further activity was detectable, and in blood and urine for comparable periods in 2 patients. Table II shows that in 3 of 5 patients the recovery in the feces was 100%; since no radioactivity was detectable in any of the blood or urine samples, it seems unlikely that a soluble form of 51Cr had been absorbed from the intestine.
Fecal flow correction. Patients given 300 mg of CrO03 per day in divided doses with each formula feeding are, in effect, ingesting 1 mg/2.08 min. Thus, if the steady state is reached and the marker is dispersed evenly in the feces, each milligram of marker excreted represents that portion of feces formed every 2.08 min. If the amount of Cr203 excreted per unit time is known, the measured daily output of feces (or of fecal constituents) can be corrected for irregularities of elimination of feces from the large bowel. Thus, the daily Cr202 intake (mg) divided by the fecal Cr,03 concentration (mg/g of feces) gives a corrected(ldaily fecal weight. After this correction, the (lay-to-day variation of fecal weights (or of fecal constituents) should be decreased, providing the diet is constant and the patient is in a metabolic steady state. 
DISCUSSION
The ideal marker. The need for an ideal marker for metabolic studies has long been recognized, and it is generally agreed that the criteria for ideality are: nonabsorbability, nontoxicity, uniform dispersibility relative to the fecal constituent of interest in the particular investigation, rapid attainment of the steady state (in which, on the average, excretion of the marker equals its intake), and ease of measurement.
Cr2O3 was introduced as an intestinal marker in veterinary work by Edin, Kihlen, and Nordfeldt (13) (or other enzymatic) action within the gut lumen, it becomes critically important to recognize those patients in whom such alterations are likely to occur. Table IV illustrates this latter point. The data are arranged in decreasing order of daily fecal turnover in 6 patients. Two effects of bacterial action on the sterols within the intestinal lumen were measured in each patient: (a) the degree of bacterial conversion of cholesterol to the 5,f,3a-OHand 5/8,3-keto-derivatives (coprostanol and coprostanone) and similar products derived from /8-sitosterol; and (b) the losses of dietary 18-sitosterol due to degradation of the sterol ring structure (9) (10) (11) . There is a significant (P = 0.05) inverse correlation (18) between daily fecal turnover and formation of neutral steroid conversion products from cholesterol. Stated in another way, the longer the colonic contents remained unexcreted, the greater the chance for bacteria to modify the trans A/B ring structure and 3,3-OH configuration of cholesterol. That the correlation is not perfect is probably a result of differences in bacterial flora in the 6 patients.
An inverse correlation is seen also between dailyfecal turnover and degradative losses of large amounts of dietary f6-sitosterol. Grundy, Ahrens, and Salen' have recently amassed considerable evidence that the amount of f3-sitosterol absorbed ill man is trivial, and that losses of this sterol are due to degradation of the ring structure into products no longer recognizable as steroids; moreover, they have found that the percentage losses of cholesterol and of f3-sitosterol in any one patient are exactly equal. The data in Table IV show that the degree of this degradation is correlated with the residence time of contents within the colon. Table IV illustrates the value of knowing the fecal turnover rate when studies of sterol balance are undertaken. But it seems clear that balance studies involving any fecal constituent that can be acted upon by intestinal bacteria will be more accurate and more meaningfully interpreted when daily fecal turnover is high and pool size is small. Balance studies for fat, protein, and carbohydrates (including D-xylose) come to mind in this regard.
